ArticleOPEN ACCESS

Durvalumab Induces Sustained Survival Benefit After Concurrent Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer

Journal of Clinical Oncology
DOI: 10.1200/JCO.22.00204
10Citations
Citations of this article
20Readers
Mendeley users who have this article in their library.

Cite

CITATION STYLE

APA

Pujol, J. L. (2022, April 20). Durvalumab Induces Sustained Survival Benefit After Concurrent Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. Journal of Clinical Oncology. Lippincott Williams and Wilkins. https://doi.org/10.1200/JCO.22.00204

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free